Company patents
Omeros Corporation
Omeros Corporation's patent strategy reveals a strong, albeit fluctuating, focus on core pharmaceutical areas, with Peptides & Proteins (61.8% of portfolio) and Pharmaceutical Preparations (58.8%) dominating, both experiencing significant growth in 2024 (212.5% and 144.4% YoY, respectively) before sharp declines in 2025, suggesting a highly dynamic and potentially reactive approach to patenting in these key therapeutic domains. Surprisingly, despite being a pharma company, there's a minor but consistent presence in non-pharma categories like Material & Chemical Analysis (5.9%) and Animal Husbandry / Fishing (4.4%), though these have seen a decline in recent years, with 0 patents so far in 2026 for both.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
68 US filings (since 2023) · 10 categories · 9 themes
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Patents
Showing 1-7 of 7
Immune Checkpoint Modulation